Mission Statement, Vision, & Core Values (2024) of Artivion, Inc. (AORT)

Mission Statement, Vision, & Core Values (2024) of Artivion, Inc. (AORT)

US | Healthcare | Medical - Devices | NYSE

Artivion, Inc. (AORT) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of Artivion, Inc. (AORT)

General Summary of Artivion, Inc. (AORT)

Artivion, Inc. is a medical technology company specializing in cardiac and vascular surgical technologies. Founded in 1993, the company focuses on developing innovative medical devices and solutions.

Company Products and Services

Artivion's primary product portfolio includes:

  • Surgical technologies for cardiac and vascular procedures
  • Biological tissue processing and preservation solutions
  • Medical grafts and implantable devices

Financial Performance Overview

Financial Metric 2023 Value
Total Revenue $248.6 million
Net Income $17.4 million
Gross Margin 61.3%
Operating Cash Flow $43.2 million

Market Position and Performance

Key Market Segments:

  • Cardiac Surgery Technologies
  • Vascular Surgical Solutions
  • Biological Tissue Processing

Artivion reported strong performance in 2023, with significant growth in key market segments and continued technological innovation.

Key Performance Indicators

Performance Indicator 2023 Data
Product Sales Growth 12.7%
Research & Development Investment $37.5 million
International Revenue 34.6% of total revenue

The company maintains a strong market position in cardiac and vascular medical technologies, with consistent investment in research and development.




Mission Statement of Artivion, Inc. (AORT)

Mission Statement of Artivion, Inc. (AORT)

Artivion, Inc. mission statement focuses on advancing cardiovascular and vascular surgical technologies and patient care solutions.

Core Mission Components

Innovation in Medical Technology

Artivion demonstrates commitment through specific metrics:

R&D Investment Patent Applications New Product Developments
$14.2 million (2023) 37 active patent applications 3 surgical technology platforms

Product Portfolio

  • PROACT Vascular Preservation Technology
  • BioGlue Surgical Adhesive
  • On-X Mechanical Heart Valves

Market Performance Indicators

Revenue Segment 2023 Performance
Surgical Technologies $203.4 million
Medical Devices $86.7 million

Strategic Focus Areas

Key Strategic Priorities:

  • Cardiovascular surgical solutions
  • Vascular preservation technologies
  • Advanced medical device engineering

Clinical Impact Metrics

Surgical Procedures Supported Annual Volume
Cardiac Surgeries 87,500+
Vascular Interventions 62,300+



Vision Statement of Artivion, Inc. (AORT)

Vision Statement Overview of Artivion, Inc. (AORT) in 2024

Artivion, Inc. (AORT) focuses on developing and delivering innovative medical technologies in cardiovascular and surgical markets.

Key Vision Components

Global Medical Innovation Leadership

Artivion aims to maintain leadership in cardiovascular medical technologies with specific strategic objectives:

  • Market capitalization of $428.6 million as of January 2024
  • Revenue generation of $237.4 million in fiscal year 2023
  • Research and development investment of $22.1 million annually
Technology Development Strategy
Technology Focus Area Investment (2024) Expected Market Impact
Surgical Technologies $14.3 million Expand global surgical intervention solutions
Cardiovascular Devices $16.7 million Enhance minimally invasive treatment options
Market Expansion Objectives

Geographic and product diversification targets for 2024:

  • Expand presence in European cardiovascular markets
  • Increase international revenue by 12.4%
  • Launch 3 new medical device technologies
Technological Innovation Metrics
Innovation Parameter 2024 Target
Patent Applications 7 new applications
R&D Personnel 82 specialized researchers
Clinical Trial Investments $8.6 million



Core Values of Artivion, Inc. (AORT)

Core Values of Artivion, Inc. (AORT) in 2024

Patient-Centered Innovation

Artivion focuses on developing advanced medical technologies that directly improve patient outcomes.

R&D Investment New Product Development
$12.3 million in 2023 3 new surgical technologies in development

Commitment to Quality and Safety

Rigorous quality control and patient safety standards are paramount in Artivion's operations.

  • ISO 13485:2016 Medical Devices Quality Management System certification
  • Zero major regulatory compliance violations in 2023
  • 99.7% product quality compliance rate

Ethical Business Practices

Maintaining highest standards of corporate integrity and transparency.

Compliance Metrics Value
Annual Ethics Training Completion 100% of employees
Whistleblower Reports Investigated 100% resolution rate

Continuous Learning and Development

Investment in employee professional growth and skill enhancement.

  • $1.5 million allocated for employee training in 2024
  • Average 40 hours of professional development per employee
  • Internal leadership development program covering 15% of workforce

Environmental Sustainability

Commitment to reducing environmental impact and promoting sustainable practices.

Sustainability Metric 2024 Target
Carbon Emission Reduction 15% from 2022 baseline
Renewable Energy Usage 25% of total energy consumption

DCF model

Artivion, Inc. (AORT) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.